Johnson & Johnson (NYSE:JNJ) Shares Up 3.4% – Time to Buy?

Johnson & Johnson (NYSE:JNJ)’s share price traded up 3.4% during trading on Thursday . The stock traded as high as $263.10 and last traded at $262.5160. 7,896,074 shares traded hands during trading, a decline of 7% from the average daily volume of 8,484,739 shares. The stock had previously closed at $253.98.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson launched its Dual-Energy THERMOCOOL SMARTTOUCH SF cardiac ablation platform in Europe, expanding its presence in electrophysiology and adding another commercial growth driver for its MedTech business. Johnson & Johnson (JNJ) Launches Dual-Energy Cardiac Ablation Catheter in Europe
• Positive Sentiment: The company also received encouraging cancer-related news, including positive European regulatory developments for Tecvayli with Darzalex SC, an agreement to acquire Firefly Bio to strengthen its oncology pipeline, and a favorable talc litigation verdict that removed one legal overhang. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk
• Positive Sentiment: Several articles highlighted Johnson & Johnson as a dividend and defensive healthcare name, reinforcing investor interest in its income profile and long-term stability. Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street’s Bullish Views?
• Positive Sentiment: Market commentary also pointed to J&J’s focus on cancer and neuroscience rather than obesity drugs, which may reassure investors looking for disciplined capital allocation and durable growth areas. Johnson & Johnson (JNJ): Focused on Cancer and Neuroscience as a Top Dividend Aristocrat Stock to Buy
• Neutral Sentiment: Analysts and commentators are also watching J&J’s second-quarter Innovative Medicine results, where Stelara biosimilar pressure could offset strength from newer drugs and blockbusters, making the upcoming earnings update an important catalyst. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch
• Neutral Sentiment: Broader articles comparing J&J with AbbVie and discussing dividend-income strategies were mostly supportive background pieces, but they do not appear to be major stock-moving catalysts on their own. J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
• Negative Sentiment: Even with the recent positive headlines, J&J’s innovative-medicine growth is still being watched closely for biosimilar competition, which could pressure future revenue and keep some investors cautious. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch

Analysts Set New Price Targets

Several research firms have recently issued reports on JNJ. JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Guggenheim raised their price objective on Johnson & Johnson from $266.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, June 26th. Bank of America boosted their target price on Johnson & Johnson from $253.00 to $254.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Argus increased their target price on Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research note on Thursday, April 16th. Finally, Wells Fargo & Company lifted their price target on Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $256.70.

Johnson & Johnson Price Performance

The firm has a 50-day moving average of $232.26 and a 200-day moving average of $230.68. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The firm has a market capitalization of $631.93 billion, a P/E ratio of 30.35, a PEG ratio of 2.49 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. The firm had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company’s revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, analysts predict that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were paid a dividend of $1.34 per share. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.0%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.97%.

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Institutional Trading of Johnson & Johnson

Large investors have recently modified their holdings of the company. Adelphi Trust Co raised its position in Johnson & Johnson by 23.3% in the second quarter. Adelphi Trust Co now owns 1,855 shares of the company’s stock worth $471,000 after acquiring an additional 351 shares during the period. Eastern Bank raised its holdings in Johnson & Johnson by 125.2% in the 2nd quarter. Eastern Bank now owns 145,368 shares of the company’s stock worth $36,919,000 after purchasing an additional 80,814 shares during the period. Roxbury Financial LLC lifted its position in Johnson & Johnson by 2.4% during the second quarter. Roxbury Financial LLC now owns 4,762 shares of the company’s stock valued at $1,209,000 after purchasing an additional 110 shares in the last quarter. Global Wealth Strategies & Associates grew its holdings in Johnson & Johnson by 3.6% during the second quarter. Global Wealth Strategies & Associates now owns 2,006 shares of the company’s stock valued at $510,000 after purchasing an additional 69 shares during the period. Finally, Hamilton Wealth LLC increased its position in Johnson & Johnson by 8.9% in the first quarter. Hamilton Wealth LLC now owns 1,221 shares of the company’s stock worth $298,000 after buying an additional 100 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.